Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03623243 · ClinicalTrials.gov registry record · Phase 3
Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients
A Phase 3 study of Multiple Sclerosis and Relapsing Multiple Sclerosis, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 185
- Enrollment target
- 20
- Study locations
NCT03623243 is a Phase 3 study of Multiple Sclerosis and Relapsing Multiple Sclerosis that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 185 participants, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (68% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT03623243, a Phase 3 study of Multiple Sclerosis and Relapsing Multiple Sclerosis, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 185 participants
- Enrollment target
- 20
- Study locations
Study Summary
To assess safety and tolerability of patients converting from approved Relapsing Multiple Sclerosis (RMS) Disease Modifying Therapies (DMTs) to siponimod.
Conditions Studied
Interventions
- DRUG Siponimod
Study Locations (20)
Florida
- Novartis Investigative Site - Boca Raton
- Novartis Investigative Site - Bradenton
- MS & Neuromuscular Center of Excellence - Clearwater
- Novartis Investigative Site - Maitland
- Novartis Investigative Site - Miami
- Novartis Investigative Site - Ocala
- Novartis Investigative Site - Oldsmar
- Novartis Investigative Site - Orlando
- Novartis Investigative Site - Ormond Beach
- Novartis Investigative Site - Sarasota
Alabama
- Novartis Investigative Site - Birmingham
- Novartis Investigative Site - Cullman
- Alabama Neurology Associates - Homewood
California
- Novartis Investigative Site - Fresno
- Novartis Investigative Site - Fullerton
- Novartis Investigative Site - Irvine
Colorado
- Novartis Investigative Site - Colorado Springs
- Novartis Investigative Site - Denver
- Novartis Investigative Site - Fort Collins
Arizona
- Novartis Investigative Site - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2019-02-14 |
| Est. Completion | 2022-07-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03623243
The ClinicalTrials.gov registry entry for NCT03623243 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 185 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (68% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Siponimod is the first listed.
NCT03623243 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Florida, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT03623243 about?
NCT03623243 is a clinical study titled "Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients". To assess safety and tolerability of patients converting from approved Relapsing Multiple Sclerosis (RMS) Disease Modifying Therapies (DMTs) to siponimod.
What is the current status of trial NCT03623243?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 185 participants. The study started on 2019-02-14. Estimated completion is 2022-07-06.
What conditions does trial NCT03623243 study?
This clinical trial studies the following conditions: Multiple Sclerosis, Relapsing Multiple Sclerosis, Advancing Multiple Sclerosis.
What interventions are being tested in trial NCT03623243?
The interventions under investigation include: Siponimod (DRUG).
Who is sponsoring clinical trial NCT03623243?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03623243 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
RECRUITING · Phase 3
-
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
RECRUITING · Phase 3
-
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
ACTIVE NOT RECRUITING · Phase 3
-
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.